Drug sales in Russia fall for first time in four years

5 November 2019
russia_lake_stock_large

Sales of drugs in Russian pharmacies during the period of January-September 2019 fell by 1.5% in volume terms to 3.8 billion packages, marking the first sales’ decline in the Russian pharmaceutical retail since 2015, according to recent statistics, published by the Russian Ministry of Health and various local analyst agencies, reports The Pharma Letter’s local correspondent.

According to the DSM Group, one of Russia’s leading analytics agencies in the field of pharmaceuticals, one of reasons for this is good prevention measures, conducted by Russian veterinary and sanitary authorities, which prevented the outbreaks of flu and SARS in the country this year. In addition, another reason was the decline of purchasing power of local population.

For the entire 2019, the Ministry of Health and the DSM Group expect the market will decline by 1%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical